Maxwell Mumbach is a Founding Scientist and leads the Discovery team at Cartography Biosciences. He and the discovery team focus on multi-omic profiling of patient samples and validation of surface antigens on primary tissue. Prior to joining Cartography, he was a functional genomics scientist at Verily Life Sciences. Max received his training at the Broad Institute and then at Stanford University where he completed his graduate studies in Genetics. In his spare time, he enjoys chasing after his two year old son at the beach or park.
Recent Posts
- Cartography Biosciences Doses First Patient in Phase 1 Trial of CBI-1214, a Highly Specific T-Cell Engager for the Treatment of Colorectal Cancer
- Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens
- Cartography Receives FDA Investigational New Drug (IND) Approval and Fast Track Designation for Lead Program CBI-1214 for Colorectal Cancer
- Cartography Secures $67 Million Series B Financing to Advance Differentiated Oncology Pipeline of Antibody-Based Therapies into the Clinic
- Cartography Names Dirk Nagorsen, M.D., as Chief Medical Officer in Expansion of Its Clinical Team
Recent Comments
No comments to show.